看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。) c1 x) y8 r; H0 D: T5 u" o
# D! t' G. j5 `# G1 O) g% W) N0 k
8 [ T+ S, s8 i1 R
Currently available feasibility data for possible combination strategies.
* L* p+ o& n* Y: i; N————————————————————————————————* k4 ]$ @8 z! K& e' m
Combination Feasibility according to preliminary data
( `: Q2 Q0 l) ^, M. q& h7 |——————————————————————————————————
( D) Y$ }* ^- b8 ^" Q9 XBevacizumab + sorafenib Yes, reduced dose
# x, y% v! }& `' ^; cBevacizumab + sunitinib† No " A% \2 o: G0 a
Bevacizumab + temsirolimus Yes
) e, F6 ], z. e( \, kBevacizumab + everolimus Yes + I$ W0 k8 w- q) m' u3 h& D9 I
Sorafenib + sunitinib ?
$ T% G9 Q; }! X# g* E% E: W3 fSorafenib + temsirolimus Yes, reduced dose I# b+ Y$ ~# w; ^( p% j1 @
Sorafenib + everolimus Yes, reduced dose
( [5 [ i6 ^/ X7 G* v9 xSunitinib + temsirolimus† No
) p5 {+ h4 D) z! K, g( XSunitinib + everolimus ? ; k6 o2 b1 O4 ~* L; x
Temsirolimus + everolimus ? / Y0 Z$ R" O7 n0 b- L& K
————————————————————$ P o/ G& ~! i! V+ x( q
†Led to US FDA warning.
3 `2 P# ?7 V7 ^8 B+ j5 g# t" U* ~?: As yet unattempted combination.
9 y. y: B7 |8 S* I. W |